Bibbins-Domingo K, U. S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of internal medicine. 2016;164(12):836–45. PMID: 27064677. 10.7326/M16-0577 [PubMed: 27064677] [CrossRef]

Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. PMID: 26491760. [PubMed: 26491760]

Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. PMID: 26491756. [PubMed: 26491756]

Chubak J, Kamineni A, Buist DSM, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews (Evidence Syntheses, No. 133). Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. [PubMed: 26491758]

Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016. PMID: 26491755. [PubMed: 26491755]

American Heart Association. What is Cardiovascular Disease? https://www​.heart.org​/en/health-topics/consumer-healthcare​/what-is-cardiovascular-disease. Accessed 10/8/2019. PMID: None.

Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254–e743. PMID: 33501848. 10.1161/CIR.0000000000000950 [PubMed: 33501848] [CrossRef]

Murphy SL, Xu J, Kochanek KD, et al. Deaths: Final Data for 2018. Natl Vital Stat Rep. 2021;69(13):1–83. PMID: 33541516. [PubMed: 33541516]

Mensah GA, Wei GS, Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017;120(2):366–80. PMID: 28104770. 10.1161/CIRCRESAHA.116.309115 [PMC free article: PMC5268076] [PubMed: 28104770] [CrossRef]

Vaughan AS, Ritchey MD, Hannan J, et al. Widespread recent increases in county-level heart disease mortality across age groups. Ann Epidemiol. 2017;27(12):796–800. PMID: 29122432. 10.1016/j.annepidem.2017.10.012 [PMC free article: PMC5733620] [PubMed: 29122432] [CrossRef]

Nelson S, Whitsel L, Khavjou O, et al. Projections of cardiovascular disease prevalence and costs. RTI International; 2016. PMID: None.

Berry JD, Dyer A, Cai X, et al. Lifetime Risks of Cardiovascular Disease. New England Journal of Medicine. 2012;366(4):321–9. PMID: 22276822. 10.1056/NEJMoa1012848 [PMC free article: PMC3336876] [PubMed: 22276822] [CrossRef]

Kressin NR, Orner MB, Manze M, et al. Understanding contributors to racial disparities in blood pressure control. Circ Cardiovasc Qual Outcomes. 2010;3(2):173–80. PMID: 20233981. 10.1161/CIRCOUTCOMES.109.860841 [PMC free article: PMC2841788] [PubMed: 20233981] [CrossRef]

Rao S, Segar MW, Bress AP, et al. Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-Reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT). JAMA Cardiol. 2020. PMID: 33185651. 10.1001/jamacardio.2020.6566 [PMC free article: PMC7666434] [PubMed: 33185651] [CrossRef]

American Cancer Society. Cancer Facts & Figures 2020. Atlanta, GA: 2020. PMID: None.

National Cancer Institute Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: Colorectal Cancer. https://seer​.cancer.gov​/statfacts/html/colorect.html. Accessed Nov. 23, 2020. PMID: None.

Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA: a cancer journal for clinicians. 2020;70(3):145–64. PMID: None. 10.3322/caac.21601 [PubMed: 32133645] [CrossRef]

Loomans-Kropp HA, Umar A. Increasing Incidence of Colorectal Cancer in Young Adults. J Cancer Epidemiol. 2019;2019:9841295. PMID: 31827515. 10.1155/2019/9841295 [PMC free article: PMC6885269] [PubMed: 31827515] [CrossRef]

Joseph DA, King JB, Dowling NF, et al. Vital Signs: Colorectal Cancer Screening Test Use - United States, 2018. MMWR Morbidity and mortality weekly report. 2020;69(10):253–9. PMID: 32163384. 10.15585/mmwr.mm6910a1 [PMC free article: PMC7075255] [PubMed: 32163384] [CrossRef]

Centers for Disease Control and Prevention. Know your risk for heart disease. https://www​.cdc.gov/heartdisease​/risk_factors.htm. Accessed 11/20/20. PMID: None.

Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73. PMID: 24222018. 10.1161/01.cir.0000437741.48606.98 [PubMed: 24222018] [CrossRef]

Anonymous. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force. Annals of internal medicine. 2016;164(12). PMID: 27064765. 10.7326/P16-9015 [PubMed: 27064765] [CrossRef]

Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. Jama. 2016;316(19):1997–2007. PMID: 27838723. 10.1001/jama.2016.15450 [PubMed: 27838723] [CrossRef]

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019:Cir0000000000000678. PMID: 30879355. 10.1161/cir.0000000000000678 [CrossRef]

Dehmer SP, Maciosek MV, Grossman ES. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report. 2021. PMID: None. [PubMed: 26491755]

PDQ® Screening and Prevention Editorial Board. Colorectal Cancer Prevention (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD)2002.

American Cancer Society. About Colorectal Cancer. https://www​.cancer.org​/cancer/colon-rectal-cancer​/about/key-statistics.html. Accessed 9/26/2019. PMID: None.

Usher-Smith JA, Walter FM, Emery JD, et al. Risk Prediction Models for Colorectal Cancer: A Systematic Review. Cancer Prev Res (Phila Pa). 2016;9(1):13–26. PMID: 26464100. 10.1158/1940-6207.CAPR-15-0274 [PMC free article: PMC7610622] [PubMed: 26464100] [CrossRef]

Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139–e596. PMID: 31992061. 10.1161/CIR.0000000000000757 [PubMed: 31992061] [CrossRef]

Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol. 2011;25(4–5):461–72. PMID: 22122763. 10.1016/j.bpg.2011.10.015 [PMC free article: PMC3354696] [PubMed: 22122763] [CrossRef]

Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiological reviews. 2008;88(4):1547–65. PMID: 18923189. 10.1152/physrev.00004.2008 [PubMed: 18923189] [CrossRef]

Nemerovski CW, Salinitri FD, Morbitzer KA, et al. Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy. 2012;32(11):1020–35. PMID: 23019080. 10.1002/phar.1127 [PubMed: 23019080] [CrossRef]

Abramson S, Howard R. Aspirin: Mechanisms of action, major toxicities, and use in rheumatic diseases. 2014. PMID: None.

Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheumatic diseases clinics of North America. 1999;25(2):359–78. PMID: 10356423. [PubMed: 10356423]

Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes care. 2010;33(6):1395–402. PMID: 20508233. 10.2337/dc10-0555 [PMC free article: PMC2875463] [PubMed: 20508233] [CrossRef]

National Institute for Health and Care Excellence Clinical Knowledge Summaries. Antiplatelet treatment: Primary prevention of CVD Last revised September 2018. https://www​.aspirin-foundation​.com/scientific-information​/guidelines​/uk-guidelines-aspirin​/#:~:text=NICE​%20CKS%20Antiplatelet​%20treatment%3A​%20Primary,stroke%20or​%20myocardial%20infarction​.%E2%80%9D%20The. Accessed. PMID: None.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37(29):2315–81. PMID: 27222591. 10.1093/eurheartj/ehw106 [PMC free article: PMC4986030] [PubMed: 27222591] [CrossRef]

Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. SIGN Publication No. 149. https://www​.sign.ac.uk/assets/sign149​.pdf. Accessed Nov 7, 2019. PMID: None.

O’Brien CW, Juraschek SP, Wee CC. Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey. Annals of internal medicine. 2019. PMID: 31330542. 10.7326/M19-0953 [PMC free article: PMC7251544] [PubMed: 31330542] [CrossRef]

Macrae F, Chetcuti A, Julie Clarke, et al. PPR1: What is the risk-benefit ratio for use of aspirin for prevention of colorectal cancer stratified by risk of colorectal cancer itself? (What is the optimal dose and frequency of administration?) [Version URL: https://wiki​.cancer.org​.au/australiawiki/index​.php?oldid=196954. Accessed Nov 7, 2019. PMID: None.

Shaukat A, Kahi CJ, Burke CA, et al. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Official journal of the American College of Gastroenterology| ACG. 2021;116(3):458–79. PMID: None. 10.14309/ajg.0000000000001122 [PubMed: 33657038] [CrossRef]

Liang PS, Shaukat A, Crockett SD. AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review. Clin Gastroenterol Hepatol. 2021. PMID: 33581359. 10.1016/j.cgh.2021.02.014 [PubMed: 33581359] [CrossRef]

Dehmer SP, Maciosek MV, Flottemesch TJ, et al. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Annals of internal medicine. 2016;164(12):777–86. PMID: 27064573. 10.7326/M15-2129 [PubMed: 27064573] [CrossRef]

United Nations Development Programme. Human Development Indices and Indicators: 2018 Statistical Update. New York, NY: 2018. PMID: None.

The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet (London, England). 1998;351(9098):233–41. PMID: 9457092. [PubMed: 9457092]

U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. Rockville, MD: U.S. Preventive Services Task Force; 2015. PMID: None.

Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064–89. PMID: 23652265. 10.1161/STR.0b013e318296aeca [PubMed: 23652265] [CrossRef]

Morton SC MM, O’Connor E, Lee CS, Booth M, Vandermeer BW, Snowden JM, D’Anci KE, Fu R, Gartlehner G, Wang Z, Steele DW. Quantitative Synthesis—An Update. Methods Guide for Comparative Effectiveness Reviews.(Prepared by the Scientific Resource Center under Contract No. 290-2012-0004-C). AHRQ Publication No. 18-EHC007-EF. Rockville, MD: Agency for Healthcare Research and Quality: 2018. PMID: None.

Buring JE, I-Min L. Personal communication. Updated WHS data ed2020. PMID: None.

Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849–60. PMID: 19482214. 10.1016/s0140-6736(09)60503-1 [PMC free article: PMC2715005] [PubMed: 19482214] [CrossRef]

Baigent C. Personal communication. 2020. PMID: None.

Berkman ND, Lohr KN, Ansari M, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2014. p. 314–49. PMID: 24404627.

Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. PMID: 15615589. 10.1186/1472-6963-4-38 [PMC free article: PMC545647] [PubMed: 15615589] [CrossRef]

McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379(16):1519–28. PMID: 30221595. 10.1056/NEJMoa1803955 [PMC free article: PMC6433466] [PubMed: 30221595] [CrossRef]

Ascend Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529–39. PMID: 30146931. 10.1056/NEJMoa1804988 [PubMed: 30146931] [CrossRef]

Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2018;392(10152):1036–46. PMID: 30158069. 10.1016/S0140-6736(18)31924-X [PMC free article: PMC7255888] [PubMed: 30158069] [CrossRef]

Saito Y, Okada S, Ogawa H, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2017;135(7):659–70. PMID: 27881565. 10.1161/CIRCULATIONAHA.116.025760 [PubMed: 27881565] [CrossRef]

Uchiyama S, Ishizuka N, Shimada K, et al. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. Stroke. 2016;47(6):1605–11. PMID: 27165949. 10.1161/STROKEAHA.115.012461 [PubMed: 27165949] [CrossRef]

Anonymous. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med. 1989;321(3):129–35. PMID: 2664509. 10.1056/NEJM198907203210301 [PubMed: 2664509] [CrossRef]

Physicians’ Health Study Research Group. Preliminary Report: Findings From the Aspirin Component of The Ongoing Physicians’ Health Study. New England Journal of Medicine. 1988;318:262–4. PMID: 3275899. 10.1056/NEJM198801283180431 [PubMed: 3275899] [CrossRef]

Cook NR, Hebert PR, Manson JE, et al. Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the physicians’s health study. Archives of Internal Medicine. 2000;160(7):921–8. PMID: 10761956. 10.1001/archinte.160.7.921 [PubMed: 10761956] [CrossRef]

Cook NR, Cole SR, Hennekens CH. Use of a Marginal Structural Model to Determine the Effect of Aspirin on Cardiovascular Mortality in the Physicians’ Health Study. American Journal of Epidemiology. 2002;155(11):1045–53. PMID: 12034583. 10.1093/aje/155.11.1045 [PubMed: 12034583] [CrossRef]

Kurth T, Glynn RJ, Walker AM, et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation. 2003;108(10):1191–5. PMID: 12939216. 10.1161/01.CIR.0000087593.07533.9B [PubMed: 12939216] [CrossRef]

Roncaglioni M, Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. The Lancet. 2001;357(9250):89–95. PMID: 11197445. 10.1016/s0140-6736(00)03539-x [PubMed: 11197445] [CrossRef]

Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ (Clinical research ed). 2000;321(7252):13–7. PMID: 10875825. 10.1136/bmj.321.7252.13 [PMC free article: PMC27417] [PubMed: 10875825] [CrossRef]

Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (Clinical research ed). 2008;337:1–10. PMID: 18927173. 10.1136/bmj.a1840 [PMC free article: PMC2658865] [PubMed: 18927173] [CrossRef]

Sacco M, Pellegrini F, Roncaglioni MC, et al. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice. Diabetes care. 2003;26(12):3264–72. PMID: None. [PubMed: 14633812]

Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Jama. 2006;295(3):306–13. PMID: 16418466. 10.1001/jama.295.3.306 [PubMed: 16418466] [CrossRef]

Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. Jama. 2010;303(9):841–8. PMID: 20197530. 10.1001/jama.2010.221 [PubMed: 20197530] [CrossRef]

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (London, England). 1998;351(9118):1755–62. PMID: 9635947. 10.1016/s0140-6736(98)04311-6 [PubMed: 9635947] [CrossRef]

Anonymous. The Hypertension Optimal Treatment Study (the HOT Study). Blood Press. 1993;2(1):62–8. PMID: 8193735. 10.3109/08037059309077529 [PubMed: 8193735] [CrossRef]

Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press. 1994;3(5):322–7. PMID: 7866597. 10.3109/08037059409102281 [PubMed: 7866597] [CrossRef]

Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender. Blood Press. 1995;4(5):313–9. PMID: 8535554. 10.3109/08037059509077613 [PubMed: 8535554] [CrossRef]

Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press. 1997;6(5):313–7. PMID: 9360003. 10.3109/08037059709062088 [PubMed: 9360003] [CrossRef]

Zanchetti A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001;19(6):1149–59. PMID: 11403365. [PubMed: 11403365]

Zanchetti A, Hansson L, Menard J, et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study. J Hypertens. 2001;19(4):819–25. PMID: 11330886. [PubMed: 11330886]

Zanchetti A, Hansson L, Dahlof B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301–7. PMID: 12409970. [PubMed: 12409970]

Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology. 2010;56(12):956–65. PMID: 20828648. 10.1016/j.jacc.2010.02.068 [PubMed: 20828648] [CrossRef]

Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens. 2000;18(5):629–42. PMID: 10826567. 10.1097/00004872-200018050-00017 [PubMed: 10826567] [CrossRef]

Zanchetti A. Aspirin and Antiplatet Drugs in the Prevention of Cardiovascular Complications of Diabetes. Pharmacotherapy of diabetes: new developments: improving life and prognosis for diabetic patients. New York, New York: Springer Science and Business Media; 2007. p. 211–8.

Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum appears in JAMA. 2009 May 13;301(18):1882]. Jama. 2008;300(18):2134–41. PMID: 18997198. [PubMed: 18997198]

Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313–6. PMID: 3125882. 10.1136/bmj.296.6618.313 [PMC free article: PMC2544821] [PubMed: 3125882] [CrossRef]

Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304. PMID: 15753114. 10.1056/NEJMoa050613 [PubMed: 15753114] [CrossRef]

Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the Women’s Health Study. J Womens Health Gend Based Med. 2000;9(1):19–27. PMID: 10718501. 10.1089/152460900318911 [PubMed: 10718501] [CrossRef]

Christen WG, Glynn RJ, Chew EY, et al. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology. 2009;116(12):2386–92. PMID: 19815293. 10.1016/j.ophtha.2009.05.031 [PMC free article: PMC2787838] [PubMed: 19815293] [CrossRef]

Rist PM, Buring JE, Kase CS, et al. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women. Stroke. 2013;44(2):432–6. PMID: 23306328. 10.1161/STROKEAHA.112.672451 [PMC free article: PMC3552068] [PubMed: 23306328] [CrossRef]

Dorresteijn JA, Visseren FL, Ridker PM, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. European heart journal. 2011;32(23):2962–9. PMID: 22090661. 10.1093/eurheartj/ehr423 [PMC free article: PMC3227855] [PubMed: 22090661] [CrossRef]

Okada S, Morimoto T, Ogawa H, et al. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes care. 2011;34(6):1277–83. PMID: 21515838. 10.2337/dc10-2451 [PMC free article: PMC3114321] [PubMed: 21515838] [CrossRef]

Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes care. 2011;34(2):280–5. PMID: 21270185. 10.2337/dc10-1615 [PMC free article: PMC3024334] [PubMed: 21270185] [CrossRef]

Soejima H, Ogawa H, Morimoto T, et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circ J. 2012;76(6):1526–32. PMID: 22447019. 10.1253/circj.cj-11-1033 [PubMed: 22447019] [CrossRef]

Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Jama. 2014;312(23):2510–20. PMID: 25401325. 10.1001/jama.2014.15690 [PubMed: 25401325] [CrossRef]

Flossmann E, Rothwell PM, British Doctors Aspirin T, et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (London, England). 2007;369(9573):1603–13. PMID: 17499602. 10.1016/S0140-6736(07)60747-8 [PubMed: 17499602] [CrossRef]

Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (London, England). 2010;376(9754):1741–50. PMID: 20970847. 10.1016/S0140-6736(10)61543-7 [PubMed: 20970847] [CrossRef]

The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet (London, England). 1991;338(8779):1345–9. PMID: 1682734. [PubMed: 1682734]

Okada S, Morimoto T, Ogawa H, et al. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J. 2013;77(12):3023–8. PMID: 24042256. 10.1253/circj.cj-13-0307 [PubMed: 24042256] [CrossRef]

Soejima H, Ogawa H, Morimoto T, et al. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial. Journal of Cardiology. 2013;62(3):165–70. PMID: 23778008. [PubMed: 23778008]

Sugawara M, Goto Y, Yamazaki T, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). American Journal of Cardiovascular Drugs. 2019;19(3):299–311. PMID: 30565155. 10.1007/s40256-018-0313-0 [PubMed: 30565155] [CrossRef]

Luo PJ, Lin XH, Lin CC, et al. Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. J Formos Med Assoc. 2019;118(5):939–44. PMID: 30366771. 10.1016/j.jfma.2018.10.007 [PubMed: 30366771] [CrossRef]

Wolfe R, Murray AM, Woods RL, et al. The aspirin in reducing events in the elderly trial: Statistical analysis plan. International Journal of Stroke. 2018;13(3):335–8. PMID: 29111960. 10.1177/1747493017741383 [PMC free article: PMC6380180] [PubMed: 29111960] [CrossRef]

Bowman L, Mafham M, Stevens W, et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal. 2018;198:135–44. PMID: 29653635. 10.1016/j.ahj.2017.12.006 [PMC free article: PMC5971211] [PubMed: 29653635] [CrossRef]

McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine. 2018;379(16):1509–18. PMID: 30221597. 10.1056/NEJMoa1805819 [PMC free article: PMC6289056] [PubMed: 30221597] [CrossRef]

McNeil JJ, Woods RL, Nelson MR, et al. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. New England Journal of Medicine. 2018;379(16):1499–508. PMID: 30221596. 10.1056/NEJMoa1800722 [PMC free article: PMC6426126] [PubMed: 30221596] [CrossRef]

Okada S, Morimoto T, Ogawa H, et al. Effect of Aspirin on Cancer Chemoprevention in Japanese Patients With Type 2 Diabetes: 10-Year Observational Follow-up of a Randomized Controlled Trial. Diabetes care. 2018;41(8):1757–64. PMID: 29909377. 10.2337/dc18-0368 [PubMed: 29909377] [CrossRef]

Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials [Electronic Resource]. 2016;17(1):286. PMID: 27296091. 10.1186/s13063-016-1354-9 [PMC free article: PMC4907276] [PubMed: 27296091] [CrossRef]

McNeil JJ, Woods RL, Nelson MR, et al. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci. 2017;72(11):1586–93. PMID: 28329340. 10.1093/gerona/glw342 [PMC free article: PMC5861878] [PubMed: 28329340] [CrossRef]

Chen WC, Lin KH, Huang YT, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Alimentary Pharmacology & Therapeutics. 2017;45(12):1542–50. PMID: 28449186. 10.1111/apt.14079 [PubMed: 28449186] [CrossRef]

Jung M, Lee S. Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. Drugs Aging. 2020;37(1):43–55. PMID: 31755069. 10.1007/s40266-019-00723-3 [PubMed: 31755069] [CrossRef]

Yokoyama K, Ishizuka N, Uemura N, et al. Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Research And Practice In Thrombosis And Haemostasis. 2018;2(2):274–81. PMID: 30046729. 10.1002/rth2.12097 [PMC free article: PMC6055501] [PubMed: 30046729] [CrossRef]

Margolis KL, Mahady SE, Nelson MR, et al. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemporary Clinical Trials Communications. 2018;11:30–6. PMID: 30023457. 10.1016/j.conctc.2018.05.015 [PMC free article: PMC6022241] [PubMed: 30023457] [CrossRef]

Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. Jama. 2005;294(1):47–55. PMID: 15998890. 10.1001/jama.294.1.47 [PubMed: 15998890] [CrossRef]

Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–54. PMID: 1783914. 10.1136/jnnp.54.12.1044 [PMC free article: PMC1014676] [PubMed: 1783914] [CrossRef]

Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Annals of internal medicine. 2013;159(2):77–85. PMID: 23856681. 10.7326/0003-4819-159-2-201307160-00002 [PMC free article: PMC3713531] [PubMed: 23856681] [CrossRef]

Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Annals of internal medicine. 1998;128(9):713–20. PMID: 9556464. 10.7326/0003-4819-128-9-199805010-00003 [PubMed: 9556464] [CrossRef]

Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. Journal of the National Cancer Institute. 1993;85(15):1220–4. PMID: 8331682. 10.1093/jnci/85.15.1220 [PubMed: 8331682] [CrossRef]

Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol. 2001;119(8):1143–9. PMID: 11483080. 10.1001/archopht.119.8.1143 [PubMed: 11483080] [CrossRef]

Buring JE, Hennekens CH. The Women’s Health Study: summary of the study design. J Myocardial Ischemia. 1992;4(3):27–9. PMID: None.

de Berardis G, Lucisano G, D’Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. Jama. 2012;307(21):2286–94. PMID: 22706834. 10.1001/jama.2012.5034 [PubMed: 22706834] [CrossRef]

Ekstrom N, Cederholm J, Zethelius B, et al. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open. 2013;3(4):1–9. PMID: 23604419. 10.1136/bmjopen-2013-002688 [PMC free article: PMC3641436] [PubMed: 23604419] [CrossRef]

Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Annals of internal medicine. 2007;147(8):525–33. PMID: 17938390. 10.7326/0003-4819-147-8-200710160-00004 [PubMed: 17938390] [CrossRef]

Huang ES, Strate LL, Ho WW, et al. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS ONE. 2010;5(12):e15721. PMID: 21209949. 10.1371/journal.pone.0015721 [PMC free article: PMC3012090] [PubMed: 21209949] [CrossRef]

Huang ES, Strate LL, Ho WW, et al. Long-term use of aspirin and the risk of gastrointestinal bleeding. American Journal of Medicine. 2011;124(5):426–33. PMID: 21531232. 10.1016/j.amjmed.2010.12.022 [PMC free article: PMC3086018] [PubMed: 21531232] [CrossRef]

Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke. 1999;30(9):1764–71. PMID: 10471421. 10.1161/01.str.30.9.1764 [PubMed: 10471421] [CrossRef]

Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. Jama. 1991;266(4):521–7. PMID: 2061978. [PubMed: 2061978]

Meade TW, Roderick PJ, Brennan PJ, et al. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 1992;68(1):1–6. PMID: 1514166. [PubMed: 1514166]

Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust. 2008;189(2):105–9. PMID: 18637782. 10.5694/j.1326-5377.2008.tb01932.x [PubMed: 18637782] [CrossRef]

Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes care. 2003;26(12):3264–72. PMID: 14633812. 10.2337/diacare.26.12.3264 [PubMed: 14633812] [CrossRef]

Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 1993;54(1):84–9. PMID: 8330469. 10.1038/clpt.1993.115 [PubMed: 8330469] [CrossRef]

Strate LL, Liu YL, Huang ES, et al. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology. 2011;140(5):1427–33. PMID: 21320500. 10.1053/j.gastro.2011.02.004 [PMC free article: PMC3081980] [PubMed: 21320500] [CrossRef]

ASPREE. ASPrin in Reducing Events in the Elderly Protocol Version 9. https://aspree​.org/usa​/wp-content/uploads​/sites/3/2014/04/ASPREE-Protocol-Version-9_-Nov2014_FINAL​.pdf. Accessed June 3, 2020. PMID: None.

Mahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2020. PMID: 32747412. 10.1136/gutjnl-2020-321585 [PMC free article: PMC7957959] [PubMed: 32747412] [CrossRef]

McNeil JJ, Gibbs P, Orchard SG, et al. Effect of aspirin on cancer incidence and mortality in older adults. Journal of the National Cancer Institute. 2020. PMID: 32778876. 10.1093/jnci/djaa114 [PMC free article: PMC7936068] [PubMed: 32778876] [CrossRef]

Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486–97. PMID: 11368702. 10.1001/jama.285.19.2486 [PubMed: 11368702] [CrossRef]

Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. Jama. 2019;321(3):277–87. PMID: 30667501. 10.1001/jama.2018.20578 [PMC free article: PMC6439678] [PubMed: 30667501] [CrossRef]

Haykal T, Barbarawi M, Zayed Y, et al. Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2019;145(7):1795–809. PMID: 31098750. 10.1007/s00432-019-02932-0 [PubMed: 31098750] [CrossRef]

Christiansen M, Grove EL, Hvas AM. Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis. Semin Thromb Hemost. 2019;45(5):478–89. PMID: 31096304. 10.1055/s-0039-1687905 [PubMed: 31096304] [CrossRef]

Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. Journal of the American College of Cardiology. 2019;73(23):2915–29. PMID: 31196447. 10.1016/j.jacc.2019.03.501 [PubMed: 31196447] [CrossRef]

Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. European heart journal. 2019;40(7):607–17. PMID: 30561620. 10.1093/eurheartj/ehy813 [PubMed: 30561620] [CrossRef]

Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: A Systematic Evidence Report for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018. PMID: 30234933. [PubMed: 30234933]

Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. Jama. 2014;311(14):1406–15. PMID: 24682252. 10.1001/jama.2014.2630 [PMC free article: PMC4189930] [PubMed: 24682252] [CrossRef]

DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Annals of internal medicine. 2015;162(4):266–75. PMID: 25686167. 10.7326/M14-1281 [PMC free article: PMC4414494] [PubMed: 25686167] [CrossRef]

Cook NR, Ridker PM. Calibration of the Pooled Cohort Equations for Atherosclerotic Cardiovascular Disease: An Update. Annals of internal medicine. 2016;165(11):786–94. PMID: 27723890. 10.7326/M16-1739 [PubMed: 27723890] [CrossRef]

Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of Cardiovascular Risk Prediction Varies by Neighborhood Socioeconomic Position: A Retrospective Cohort Study. Annals of internal medicine. 2017;167(7):456–64. PMID: 28847012. 10.7326/M16-2543 [PMC free article: PMC6435027] [PubMed: 28847012] [CrossRef]

Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. Jama. 2014;311(14):1416–23. PMID: 24681960. 10.1001/jama.2014.2632 [PubMed: 24681960] [CrossRef]

Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. Journal of the American College of Cardiology. 2016;67(18):2118–30. PMID: 27151343. 10.1016/j.jacc.2016.02.055 [PMC free article: PMC5097466] [PubMed: 27151343] [CrossRef]

Ko DT, Sivaswamy A, Sud M, et al. Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations. CMAJ. 2020;192(17):E442–E9. PMID: 32392491. 10.1503/cmaj.190848 [PMC free article: PMC7207198] [PubMed: 32392491] [CrossRef]

De Filippis AP, Young R, McEvoy JW, et al. Risk score overestimation: The impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. European heart journal. 2017;38(8):598–608. PMID: 27436865. 10.1093/eurheartj/ehw301 [PMC free article: PMC5837662] [PubMed: 27436865] [CrossRef]

Mora S, Wenger NK, Cook NR, et al. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women’s Health Initiative. JAMA Internal Medicine. 2018;178(9):1231–40. PMID: 30039172. 10.1001/jamainternmed.2018.2875 [PMC free article: PMC6142964] [PubMed: 30039172] [CrossRef]

Colantonio LD, Richman JS, Carson AP, et al. Performance of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations by Social Deprivation Status. J Am Heart Assoc. 2017;6(3). PMID: 28314800. 10.1161/JAHA.117.005676 [PMC free article: PMC5524046] [PubMed: 28314800] [CrossRef]

Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet (London, England). 2018;391(10133):1897–907. PMID: 29735391. 10.1016/s0140-6736(18)30664-0 [PubMed: 29735391] [CrossRef]

Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Annals of internal medicine. 2015;162(1):W1–73. PMID: 25560730. 10.7326/M14-0698 [PubMed: 25560730] [CrossRef]

Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4(4). PMID: 25888372. 10.1161/JAHA.115.001888 [PMC free article: PMC4579932] [PubMed: 25888372] [CrossRef]

Yadlowsky S, Hayward RA, Sussman JB, et al. Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk. Annals of internal medicine. 2018;169(1):20–9. PMID: 29868850. 10.7326/M17-3011 [PubMed: 29868850] [CrossRef]

Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141(19):1541–53. PMID: 32233663. 10.1161/CIRCULATIONAHA.119.045010 [PMC free article: PMC7217722] [PubMed: 32233663] [CrossRef]

Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. PMID: 16504638. 10.1016/j.ahj.2005.04.017 [PubMed: 16504638] [CrossRef]

Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Annals of internal medicine. 1999;131(12):927–34. PMID: 10610643. 10.7326/0003-4819-131-12-199912210-00004 [PubMed: 10610643] [CrossRef]

Donze J, Rodondi N, Waeber G, et al. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med. 2012;125(11):1095–102. PMID: 22939362. 10.1016/j.amjmed.2012.04.005 [PubMed: 22939362] [CrossRef]

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. PMID: 20299623. 10.1378/chest.10-0134 [PubMed: 20299623] [CrossRef]

Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ (Clinical research ed). 2014;349:g4606. PMID: 25069704. 10.1136/bmj.g4606 [PMC free article: PMC4113281] [PubMed: 25069704] [CrossRef]

Selak V, Jackson R, Poppe K, et al. Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. Annals of internal medicine. 2019;170(6):357–68. PMID: 30802900. 10.7326/M18-2808 [PubMed: 30802900] [CrossRef]

de Groot NL, Hagenaars MP, Smeets HM, et al. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. J Gastroenterol. 2014;49(2):245–53. PMID: 23609946. 10.1007/s00535-013-0817-y [PubMed: 23609946] [CrossRef]

Whitlock EP, Johnson ES. Are We There Yet? Another Milepost in the Journey to Identify Appropriate Candidates for Aspirin Primary Prevention. Annals of internal medicine. 2019;170(6):411–3. PMID: 30802898. 10.7326/M19-0416 [PubMed: 30802898] [CrossRef]

Dugani S, Ames JM, Manson JE, et al. Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Curr Atheroscler Rep. 2018;20(3):15. PMID: 29464356. 10.1007/s11883-018-0717-y [PubMed: 29464356] [CrossRef]

Coon SA, Brooks AD, Wolff SE. Primary prevention aspirin use in high-risk patients: A pharmacist intervention and comparison of risk stratification tools. J Am Pharm Assoc (2003). 2017;57(5):585–90. PMID: 28811088. 10.1016/j.japh.2017.07.003 [PubMed: 28811088] [CrossRef]

Selak V, Jackson R, Poppe K, et al. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. Annals of internal medicine. 2019. PMID: 31525775. 10.7326/M19-1132 [PubMed: 31525775] [CrossRef]

Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124(6):519–26. PMID: 21605729. 10.1016/j.amjmed.2011.01.007 [PMC free article: PMC3101476] [PubMed: 21605729] [CrossRef]

Jung SB, Nagaraja V, Kapur A, et al. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J. 2015;45(4):409–16. PMID: 25583062. 10.1111/imj.12697 [PubMed: 25583062] [CrossRef]

Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682–91.e2. PMID: 31152740. 10.1053/j.gastro.2019.05.056 [PubMed: 31152740] [CrossRef]

Singh G, Sharma S, Kaur J, et al. Efficacy and tolerability of proton pump inhibitors in the long-term aspirin users: meta-analysis of randomized controlled trials. American journal of gastroenterology. 2016;111:S444. PMID: None. 10.1038/ajg.2016.360 [PubMed: 28763306] [CrossRef]

Garcia Rodriguez LA, Lanas A, Soriano-Gabarro M, et al. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. J Clin Med. 2020;9(4). PMID: 32231106. 10.3390/jcm9040928 [PMC free article: PMC7230296] [PubMed: 32231106] [CrossRef]

Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344(13):967–73. PMID: 11274623. 10.1056/NEJM200103293441304 [PubMed: 11274623] [CrossRef]

Sundstrom J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136(13):1183–92. PMID: 28947478. 10.1161/CIRCULATIONAHA.117.028321 [PubMed: 28947478] [CrossRef]

Gerstein NS, Albrechtsen CL, Mercado N, et al. A Comprehensive Update on Aspirin Management during Noncardiac Surgery. Anesthesia and Analgesia. 2020:1111–23. PMID: 32675638. 10.1213/ANE.0000000000005064 [PubMed: 32925332] [CrossRef]

Rodriguez LA, Cea-Soriano L, Martin-Merino E, et al. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ (Clinical research ed). 2011;343:d4094. PMID: 21771831. 10.1136/bmj.d4094 [PMC free article: PMC3139911] [PubMed: 21771831] [CrossRef]

ClinicalTrials​.gov [Internet]. Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease. https:​//clinicaltrialsgov​/show/NCT03757156 [serial on the Internet]. 2018 [cited Search 1 - CENTRALRegistries: Available from: https://www​.cochranelibrary​.com/central/doi/10​.1002/central/CN-01795153/full.

Shah R, Khan B, Latham SB, et al. A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. American Journal of Medicine. 2019;132(11):1295–304.e3. PMID: 31153866. 10.1016/j.amjmed.2019.05.015 [PubMed: 31153866] [CrossRef]

Ebell MH. Clopidogrel plus 21 days of aspirin is superior to aspirin alone within first 24 hours of TIA or minor stroke. American Family Physician. 2014;89(1):55. PMID: None.

Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013(1):CD004816. PMID: 23440795. 10.1002/14651858.CD004816.pub5 [PMC free article: PMC6481400] [PubMed: 23440795] [CrossRef]

Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. The New England journal of medicine. 2020;384:216–28. PMID: 33186492. 10.1056/NEJMoa2028220 [PMC free article: PMC7116860] [PubMed: 33186492] [CrossRef]

Qiao Y, Yang T, Gan Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18(1):288. PMID: 29534696. 10.1186/s12885-018-4156-5 [PMC free article: PMC5851082] [PubMed: 29534696] [CrossRef]

Loomans-Kropp HA, Pinsky P, Cao Y, et al. Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JAMA network open. 2019;2(12):e1916729. PMID: 31800071. 10.1001/jamanetworkopen.2019.16729 [PMC free article: PMC6902761] [PubMed: 31800071] [CrossRef]

Guo CG, Ma W, Drew DA, et al. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021. PMID: 33475710. 10.1001/jamaoncol.2020.7338 [PMC free article: PMC7821085] [PubMed: 33475710] [CrossRef]

Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet (London, England). 2018;392(10164):2583–94. PMID: 30466866. 10.1016/S0140-6736(18)31775-6 [PMC free article: PMC6294731] [PubMed: 30466866] [CrossRef]

Pommergaard HC, Burcharth J, Rosenberg J, et al. Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. Gastroenterology. 2016;150(1):114–22.e4. PMID: 26404953. 10.1053/j.gastro.2015.09.010 [PubMed: 26404953] [CrossRef]

Hull M, Sprange K, Hepburn T, et al. Randomised trial of EPA and aspirin for colorectal cancer chemoprevention: The seafood polyp prevention trial. Gut. 2018;67:A183. PMID: None. 10.1136/gutjnl-2018-BSGAbstracts.363 [CrossRef]

Ma K, Sarrafi S, Chan YM, et al. Aspirin Effect on Polyp Recurrence Depends on Polyp Subtype. Gastroenterology. 2018;154(6):S-871–S-2. PMID: None. 10.1016/S0016-5085(18)32945-7 [CrossRef]

Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ (Clinical research ed). 2016;355:i6188. PMID: 27919915. 10.1136/bmj.i6188 [PMC free article: PMC5137632] [PubMed: 27919915] [CrossRef]

Ye XF, Wang J, Shi WT, et al. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. British Journal of Cancer. 2014;111(11):2172–9. PMID: 25180765. 10.1038/bjc.2014.481 [PMC free article: PMC4260025] [PubMed: 25180765] [CrossRef]

Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (London, England). 2011;378(9809):2081–7. PMID: 22036019. 10.1016/S0140-6736(11)61049-0 [PMC free article: PMC3243929] [PubMed: 22036019] [CrossRef]

Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. The Lancet. 2020;395(10240):1855–63. PMID: 32534647. 10.1016/S0140-6736(20)30366-4 [PMC free article: PMC7294238] [PubMed: 32534647] [CrossRef]

Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (London, England). 2011;377(9759):31–41. PMID: 21144578. 10.1016/S0140-6736(10)62110-1 [PubMed: 21144578] [CrossRef]

Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (London, England). 2012;379(9826):1602–12. PMID: 22440946. 10.1016/S0140-6736(11)61720-0 [PubMed: 22440946] [CrossRef]

Elwood PC, Morgan G, Galante J, et al. Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS ONE [Electronic Resource]. 2016;11(11):e0166166. PMID: 27846246. 10.1371/journal.pone.0166166 [PMC free article: PMC5113022] [PubMed: 27846246] [CrossRef]

Lanas A, Wu P, Medin J, et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9(9):762–8 e6. PMID: 21699808. 10.1016/j.cgh.2011.05.020 [PubMed: 21699808] [CrossRef]

Lanas A, Aabakken L, Fonseca J, et al. Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther. 2011;33(11):1225–33. PMID: 21480935. 10.1111/j.1365-2036.2011.04651.x [PubMed: 21480935] [CrossRef]

Centers for Disease Control and Prevention. United States Cancer Statistics: 1999-2014, WONDER Online Database. https://wonder​.cdc.gov​/wonder/help/cancer-v2014.html. Accessed. PMID: None.

American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020. Diabetes care. 2020;43(Suppl 1):S111–S34. PMID: 31862753. https://care​.diabetesjournals​.org/content​/43/Supplement_1/S111 [PubMed: 31862753]

American Academy of Family Physicians. Clinical Preventive Service Recommendations: Aspirin Use to Prevent CVD and Colorectal Cancer. https://www​.aafp.org​/patient-care/clinical-recommendations​/all​/aspirin-use-prevention.html. Accessed 9/27/2019. PMID: None.

American Cancer Society. Can Colorectal Cancer Be Prevented? https://www​.cancer.org​/cancer/colon-rectal-cancer​/causes-risks-prevention​/prevention.html. Accessed 9/26/2019. PMID: None.

American Cancer Society. Aspirin and Cancer Prevention: What the Research Really Shows. https://www​.cancer.org​/latest-news/aspirin-and-cancer-prevention-what-the-research-really-shows.html. Accessed 9/26/2019. PMID: None.

National Institute for Health and Care Excellence. Prevention of colorectal cancer in people with Lynch syndrome. https://www​.nice.org.uk/guidance/ng151. Accessed 2/23/2021. PMID: None.

Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Online. 2013.

Anonymous. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17(2):151–83. [PubMed: 10067786]